Therapeutic effect of zoledronic acid on primary osteoporosis in elderly patients.
- Author:
Ling XU
1
;
Haiou DENG
;
Ximei ZHI
;
Weijie ZHANG
;
Xiaona WANG
;
Wen WU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; therapeutic use; Diphosphonates; therapeutic use; Female; Humans; Imidazoles; therapeutic use; Male; Osteoporosis; drug therapy; metabolism; Treatment Outcome
- From: Journal of Southern Medical University 2012;32(9):1287-1289
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of zoledronic acid on bone mineral density (BMD) and bone metabolic markers in elderly patients with primary osteoporosis.
METHODSForty-eight elderly patients with osteoporosis were randomly assigned to zoledronic acid group (n=23) to receive treatment with 5 mg zoledronic acid once a year and the control group (n=25). In both groups, the patients were given Vitamin D3 and caltrate on a daily basis for a year. The bone mineral density (BMD) and bone metabolic markers were observed after the treatment.
RESULTSCompared with the control group, zoledronic acid group had significantly higher L1-4, neck, Inter and Ward's BMD (P<0.05) with reduced B-NTX (P<0.05). The N-MID and CT showed no significant differences between the two groups (P<0.05).
CONCLUSIONZoledronic acid administration once a year can increase BMD and lower the serum bone turnover metabolism, and can be used in the treatment of primary osteoporosis in elderly patients.
